anti-hu/mo VEGFR-1/Flt-1, Antagonistic monoclonal antibody Anti-Hu/Mo 100 µg,Reliatech,mV1004.1m-h-m
This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse immunized with purified extracellular domain of recombinant human VEGFR1.
Host
Mouse
Reactivity
Human, Mouse
Application
WB, Blocking
Platform ID
BAB501694917

Reliatech
Contact
Tel: +49 (0) 5331 - 8586987
Fax: +49 (0) 5331- 8586989
Email:
Specifications
Scientific Background
Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The antibody will bind near the ligand binding site of the receptor and has antagonistic activity by blocking the binding of natural ligands.
Synonyms
vascular endothelial growth factor receptor-1; FLT1; FLT; VEGF receptor 1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
Please provide the required information below so that we can quickly source your products.
